Hepatocyte growth factor activator inhibitor

From Proteopedia

spinqualitylabelsall models Human hepatocyte growth factor activator inhibitor 1 Kunitz domain 1 (green) complex with HGFA (blue) and phosphate (PDB code 1yc0) Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image Function Hepatocyte growth factor activator inhibitor (HAI) or Kunitz-type protease inhibitor contains 2 Kunitz domains[1]. HAI-1 is a cell surface-binding protein and regulates hepatocyte growth factor activator activity in the patricellular microenvironment[2]. HAI-1 is the cognate inhibitor of HGFA and matripase. HAI-2 is more efficient inhibitor of pepsin and displays a broader inhibitory spectrum[3] Relevance Abnormal levels of HAI-1 were observed in various types of human cancer[4]. Structural highlights in the manner of other trypsin-like proteases inhibitors[5].

3D structures of hepatocyte growth factor activator inhibitor

Updated on 01-July-2024

References

1. ↑ Shimomura T, Denda K, Kitamura A, Kawaguchi T, Kito M, Kondo J, Kagaya S, Qin L, Takata H, Miyazawa K, Kitamura N. Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor. J Biol Chem. 1997 Mar 7;272(10):6370-6. PMID:9045658
2. ↑ Kataoka H, Shimomura T, Kawaguchi T, Hamasuna R, Itoh H, Kitamura N, Miyazawa K, Koono M. Hepatocyte growth factor activator inhibitor type 1 is a specific cell surface binding protein of hepatocyte growth factor activator (HGFA) and regulates HGFA activity in the pericellular microenvironment. J Biol Chem. 2000 Dec 22;275(51):40453-62. PMID:11013244 doi:http://dx.doi.org/10.1074/jbc.M006412200
3. ↑ Nakamura K, Abarzua F, Hongo A, Kodama J, Nasu Y, Kumon H, Hiramatsu Y. Hepatocyte growth factor activator inhibitor-2 (HAI-2) is a favorable prognosis marker and inhibits cell growth through the apoptotic pathway in cervical cancer. Ann Oncol. 2009 Jan;20(1):63-70. PMID:18689863 doi:10.1093/annonc/mdn556
4. ↑ Zheng Q, Wu H, Cao J, Ye J. Hepatocyte growth factor activator inhibitor type1 in cancer: advances and perspectives (Review). Mol Med Rep. 2014 Dec;10(6):2779-85. doi: 10.3892/mmr.2014.2628. Epub 2014 Oct, 13. PMID:25310042 doi:http://dx.doi.org/10.3892/mmr.2014.2628
5. ↑ Shia S, Stamos J, Kirchhofer D, Fan B, Wu J, Corpuz RT, Santell L, Lazarus RA, Eigenbrot C. Conformational lability in serine protease active sites: structures of hepatocyte growth factor activator (HGFA) alone and with the inhibitory domain from HGFA inhibitor-1B. J Mol Biol. 2005 Mar 11;346(5):1335-49. Epub 2005 Jan 28. PMID:15713485 doi:10.1016/j.jmb.2004.12.048